Literature DB >> 25120763

Unclassified renal cell carcinoma: a clinicopathological, comparative genomic hybridization, and whole-genome exon sequencing study.

Zhen-Yan Hu1, Li-Juan Pang1, Yan Qi2, Xue-Ling Kang1, Jian-Ming Hu2, Lianghai Wang1, Kun-Peng Liu1, Yuan Ren1, Mei Cui1, Li-Li Song1, Hong-An Li1, Hong Zou2, Feng Li1.   

Abstract

Unclassified renal cell carcinoma (URCC) is a rare variant of RCC, accounting for only 3-5% of all cases. Studies on the molecular genetics of URCC are limited, and hence, we report on 2 cases of URCC analyzed using comparative genome hybridization (CGH) and the genome-wide human exon GeneChip technique to identify the genomic alterations of URCC. Both URCC patients (mean age, 72 years) presented at an advanced stage and died within 30 months post-surgery. Histologically, the URCCs were composed of undifferentiated, multinucleated, giant cells with eosinophilic cytoplasm. Immunostaining revealed that both URCC cases had strong p53 protein expression and partial expression of cluster of differentiation-10 and cytokeratin. The CGH profiles showed chromosomal imbalances in both URCC cases: gains were observed in chromosomes 1p11-12, 1q12-13, 2q20-23, 3q22-23, 8p12, and 16q11-15, whereas losses were detected on chromosomes 1q22-23, 3p12-22, 5p30-ter, 6p, 11q, 16q18-22, 17p12-14, and 20p. Compared with 18 normal renal tissues, 40 mutated genes were detected in the URCC tissues, including 32 missense and 8 silent mutations. Functional enrichment analysis revealed that the missense mutation genes were involved in 11 different biological processes and pathways, including cell cycle regulation, lipid localization and transport, neuropeptide signaling, organic ether metabolism, and ATP-binding cassette transporter signaling. Our findings indicate that URCC may be a highly aggressive cancer, and the genetic alterations identified herein may provide clues regarding the tumorigenesis of URCC and serve as a basis for the development of targeted therapies against URCC in the future.

Entities:  

Keywords:  Unclassified renal cell carcinoma; chromosome imbalance; comparative genomic hybridization; exon GeneChip; gene mutation

Mesh:

Year:  2014        PMID: 25120763      PMCID: PMC4128998     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  38 in total

1.  The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study.

Authors:  Mieke Van Hemelrijck; Hans Garmo; Niklas Hammar; Ingmar Jungner; Göran Walldius; Mats Lambe; Lars Holmberg
Journal:  Int J Cancer       Date:  2011-08-03       Impact factor: 7.396

2.  A novel APOB mutation identified by exome sequencing cosegregates with steatosis, liver cancer, and hypocholesterolemia.

Authors:  Angelo B Cefalù; James P Pirruccello; Davide Noto; Stacey Gabriel; Vincenza Valenti; Namrata Gupta; Rossella Spina; Patrizia Tarugi; Sekar Kathiresan; Maurizio R Averna
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-30       Impact factor: 8.311

Review 3.  Markers of proliferation in normal and leukoplakic oral epithelia.

Authors:  S C Liu; A J Klein-Szanto
Journal:  Oral Oncol       Date:  2000-03       Impact factor: 5.337

4.  Comparative light and electron microscopic observations of the cytoplasmic matrix in renal carcinomas.

Authors:  J L Ericsson; R Seljelid; S Orrenius
Journal:  Virchows Arch Pathol Anat Physiol Klin Med       Date:  1966-10-10

5.  [Unclassified renal cell carcinoma accompanying pyonephrosis: a case report].

Authors:  Yukako Nakanishi; Kinue Aihara; Toeki Yo; Yusuke Shiraishi; Yoshikazu Togo; Rikiya Taoka; Yasuo Ueda; Toru Suzuki; Yoshihide Higuchi; Fumio Tsukuda; Masataka Zozumi; Seiichi Hirota; Akihiro Kanematsu; Michio Nojima; Shingo Yamamoto
Journal:  Hinyokika Kiyo       Date:  2012-08

6.  Key structure of brij for overcoming multidrug resistance in cancer.

Authors:  Jingling Tang; Yongjun Wang; Dun Wang; Yuhua Wang; Zhenghong Xu; Kelly Racette; Feng Liu
Journal:  Biomacromolecules       Date:  2013-01-24       Impact factor: 6.988

7.  Haplotype analysis of signal peptide (insertion/deletion) and XbaI polymorphisms of the APOB gene in gallbladder cancer.

Authors:  Sachchida Nand Pandey; Anvesha Srivastava; Manjusha Dixit; Gourdas Choudhuri; B Mittal
Journal:  Liver Int       Date:  2007-09       Impact factor: 5.828

8.  Aberrant methylation and loss of CADM2 tumor suppressor expression is associated with human renal cell carcinoma tumor progression.

Authors:  Wei He; Xuesong Li; Shuping Xu; Junkui Ai; Yanqing Gong; Jennifer L Gregg; Ruili Guan; Wei Qiu; Dianqi Xin; Jeffrey R Gingrich; Yinglu Guo; Guimin Chang
Journal:  Biochem Biophys Res Commun       Date:  2013-05-03       Impact factor: 3.575

9.  [Clinical study of undifferentiated renal cell carcinoma in comparison with well differentiated cases].

Authors:  T Onishi; T Machida; F Masuda; H Kurauchi; M Suzuki; N Iizuka; H Shirakawa
Journal:  Nihon Gan Chiryo Gakkai Shi       Date:  1989-06-20

10.  A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).

Authors:  Ana M Molina; Thomas E Hutson; James Larkin; Anne M Gold; Karen Wood; Dave Carter; Robert Motzer; M Dror Michaelson
Journal:  Cancer Chemother Pharmacol       Date:  2013-11-05       Impact factor: 3.333

View more
  2 in total

Review 1.  Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer.

Authors:  Ulka Vaishampayan
Journal:  Curr Treat Options Oncol       Date:  2018-01-24

Review 2.  Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities.

Authors:  Deepika Sirohi; Steven C Smith; Neeraj Agarwal; Benjamin L Maughan
Journal:  Res Rep Urol       Date:  2018-11-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.